Abstract
Bispecific antibodies are artificially engineered monoclonal antibodies (MAbs) that consist of two distinct binding sites and are capable of binding two different antigens noncovalently. They can be produced by chemical cross-linkage, genetic engineering, or somatic hybridization. This chapter describes a rapid method using somatic fusion to generate hybrid hybridomas (quadromas). Two fluorescence-labeled hybridoma cell lines were fused with polyethylene gly col (PEG) to generate the quadroma. Generation of a quadroma secreting bsMAb against biotin and HRPO is described, along with a benzhydroxamic acid-agarose affinity chromatography procedure to purify the bsMAb-HRPO complex. This bsMAb can be used for ultrasensitive ELISA detection of biotinylated antigens. Essentially a similar method can be used for fusing any two hybridomas for therapeutic applications. Bifunctional antibodies are colinear molecules with one or more paratopes linked with diagnostic or therapeutic molecules. There are some limitations of therapeutic monoclonal antibodies in the clinic that can be overcome by engineering smaller and more effective antibody fragments. Here we describe a stepwise procedure for developing a bifunctional ScFv (bfScFv). We constructed a bfScFv from a hybridoma cell line using PCR strategies. The VL and VH gene segments are linked with a 45-bp linker and fused with a biotin mimic sequence at the 3′ end. This engineered bifunctional antibody fragment gene could be expressed and the protein purified on a large scale in Escherichia coli as inclusion bodies. Such bifunctional antibody molecules could have useful applications in the area of immunodiagnostics and immunotherapy. Similar strategies can be used to incorporate a second single-chain antibody or any nonantibody entity such as a cytokine for therapeutic applications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
White., C. A., Weaver, R. L., and Grillo-Lopez, A. J. (2001) Antibody-targeted immuno-therapy for treament of malignancy. Annu. Rev. Med. 52, 125–145.
Kohler, G. and Milstein, C. (1975) Continuous cultures of fused secreting antibody of redefined specificity. Nature 256,495–497.
Winter, G. and Milstein, C. (1991) Man-made antibodies. Nature 349, 293–299.
Pluckthun, A. and Pack, P. (1997) New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3, 83–105.
Bird, R. E., Hardman, K. D., Jacobson, J. W., et al. (dy1988) Single-chain antigen-binding proteins. Science 242, 423–426.
Huston, J.S., Levinson, D., Mudgett-Hunter, M., et al. (dy1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85, 5879–5883.
Nisonoff, A. and Rivers, M. M. (1961) Recombination of a mixture of univalent antibody fragments of different specificity. Arch. Biochem. Biophys. 93, 460–462.
Kriangkum, J., Xu, B., Nagata, L. P., Fulton, R. E., and Suresh, M. R. (2001) Bispecific and bifunctional single chain recombinant antibodies. Biomol. Eng. 18(2), 31–40.
Suresh, M. R., Cuello, C., and Milstein, C. (1986) Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays. Proc. Natl. Acad. Sci. USA 83, 7989–7993.
Cao, Y., Christian, S., and Suresh, M. R. (1998) Development of bsMAb anti-biotin x anti-HRPO as a universal immunoprobe for detecting biotinylated macromolecules. J. Immunol. Methods 220, 85–91.
Van Ojik, H. H. and Valerius, T. (dy2001) Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy. Crit. Rev.Oncol. Hematol. 38, 47–61.
Withoff, S., Helfrich, W., de Leij, L. F. M. H., and Molema, G. (dy2001) Bi-specific antibody therapy for the treatment of cancer. Curr. Opin. Mol. Ther. 3, 53–62.
Talac, R. and Nelson, H. (2000) Current perspectives of bispecific antibody-based immu-notherapy. J. Biol. Regul. Homeost. Agents 14, 175–181.
van Spriel, A. B., van Ojik, H. H., and van De Winkel, J. G. (dy2000) Immunotherapeutic perspective for bispecific antibodies. Immunol. Today 21, 391–397.
Kroesen, B. J., Helfrich, W., Molema, G., and de Leij, L. (dy1998) Bispecific antibodies for treatment for of cancer in experimental animal models and man. Adv. Drug. Deliv. Rev. 31, 105–129.
Wang, H., Liu, Y., Wei, L., and Guo, Y. (2000) Bi-specific antibodies in cancer therapy. Adv. Exp. Med. Biol. 465, 369–380.
Koelemij, R., Kuppen, P. J., van de Velde, C. J., Fleuren, G. J., Hagenaars, M., and Eggermont, A. M. (dy1999) Bispecific antibodies in cancer therapy, from the laboratory to the clinic. J. Immunotherapy 22, 514–524.
Segal, D. M., Weiner, G. J., and Weiner, L. M. (1999) Bispecific antibodies in cancer therapy. Curr. Opin. Immunol. 11, 558–562.
Cao, Y. and Lam, L. (2003) Bispecific antibody conjugates in therapeutics. Adv. Drug. Deliv. Reviews, 55171–197.
Cao, Y. and Suresh, M. R. (1998) Bispecific antibodies as novel bioconjugates. Biocon-jugate Chemistry 9(8), 635–644.
Milstein, C. and Cuello, A. C. (1983) Hybrid hybridomas and their use in immunohis-tochemistry. Nature 305, 537–540.
Nolan, O. and Kennedy, O. R. (1990) Bifunctional antibodies: concept, production and applications. Biochem. Biophys. Acta 1040, 1–11.
Karawajew, L., Behrsing, O., Kaiser, G., and Micheel, B. (1988) Production and ELISA application of bispecific monoclonal antibodies against fluorescein isothiocyanate (FITC) and horseradish peroxidase (HRP). J. Immunol Methods 111, 95–99.
Karawajew, L., Micheel, B., Behrsing, O., and Gaestel, M. (1987) Bispecific antibody-producing hybrid bybridomas selected by a fluorescence activated cell sorter. J. Immunol Methods 96, 265–270.
Kreutz, F. T., Xu, D. Z., and Suresh, M. R. (1998) A new method to generate quadromas by electrofusion and FACS sorting. Hybridoma 17, 267–273.
Gupta, S. and Suresh, M. R. (2002) Affinity chromatography and co-chromatography of bispecific monoclonal antibody immunoconjugates. J. Biochem. Biophys. Methods 51, 203–216.
Husereau, D. R. and Suresh, M. R. (2001) A general affinity method to purify peroxidase-tagged antibodies. J. Immunol. Methods 249(1-2), 33–41.
de Ropp, J. S., Mandal, P. K., and La Mar, G. N. (dy1999) Solution 1H NMR investigation of the heme cavity and substrate binding site in cyanide-inhibited horseradish peroxidase. Biochemistry 38, 1077–1086.
Kabat, E. A., Wu, T. T., Perry, H. M., Gottesman, K. S., and Foeller, C. (1991) Sequences of Proteins of Immunological Interest, 5th Ed., U.S. Department Health and Human Services, Public Health Service, National Institute of Health, Publication No. 81-3242.
Orlandi, R., Gussow, D. H., Jones, P. T., and Winter, G. (1989) Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86, 3833–3837.
Xu, B., Kriangkum, J., Nagata, L. P., Fulton, R. E., and Suresh, M. R. (1999) A single chain Fv specific against western equine encephalitis virus. Hybridoma 18(4), 315–323.
Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
Luo, D., Geng, M., Schultes, B., et al. (1998) Expression of a fusion protein of scFv-biotin mimetic peptide for immunoassay. J. Biotechnol. 65, 225–228.
Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 277, 680–685.
Towbin, H., Staehelin, T., and Gordon, J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Proc. Natl. Acad. Sci. USA 76, 4350–4354.
Kurucz, I., Titus, J. A., Jost C. R., and Segal. D. M. (1995) Correct disulfide pairing and efficient refolding of detergent-solublilized single chain Fv proteins from bacterial inclusion bodies. Molecular Immunology 32(17/18), 1443–1452.
Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of dye binding. Anal. Biochem. 72, 248–254.
Long, M. C., Jager, S., Mah, D. C. W., et al. (2000) Construction and characterization of a novel recombinant single-chain variable fragment antibody against western equine encephalitis virus. Hybridoma 19(1), 1–13.
Rudolph, R. (1990) Renaturation of recombinant disulfide-bonded protein from "e;inclusion bodies."e; In: Modern Methods in Protein and Nucleic Acid Research. Tschesche, H., ed., Walter de Druyter, Berlin, Germany, pp. 149–171.
Buchner, J. and Rudolph, R. (1991) Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli. Biotechnology 9(2), 157–162.
Buchne, J., Pastan, I., and Brinkmann, U. (1992) A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal. Biochem. 205(2), 263–270.
Lacks, S. A. and Springhorn, S. S. (1980) Renaturation of enzymes after polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulphate. J. Biol. Chem. 255, 7467–7473.
Saxena, V. P. and Wetlaufer, D. B. (1970) Formation of three-dimensional structure in proteins. I. Rapid nonenzyme reactivation of reduced lysozyme. Biochemistry 9(25), 5015–5023.
Suttnar, J., Dyr, J. E., Hamsikova, E., Novak, J., and Vonka, V. (1994) Procedure for refolding and purification of recombinant proteins from Eschrichia coli inclusion bodies using a strong anion exchanger. J. Chromatogr. B 656, 123–126.
Wei, C., Tang, B., Zhang, Y., and Yang, K. (1999) Oxidative refolding of recombinant prochymosin. Biochem. J. 340, 345–351.
Verma, R., Boleti, E., and George, A. J. T. (1998) Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression system. J. Immunol. Methods 216, 165–181.
Clark, A.M. (2002) Standard protocols for the construction of Fab libraries. In: Methods in Molecular Biology, vol. 178: Antibody Phage Display: Methods and Protocols. O’Brien, P. M., and Aitken, R., eds. Humana, Totowa, NJ, pp. 39–58.
Dziegiel, M., Nielsen, L, K., Adersen, P. S., Blancher, A., Dickmeiss, E., and Engber, J.(1995) Phage display used for gene cloning of human recombinant antibody against the erythrocyte surface antigen, rhesus D. J. Immunol. Methods 182(1), 7–19.
Marks, J. D., Tristem, M., Karpas, A., and Winter, G. (1991) Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. Eur. J. Immunol. 21(4), 985–991.
Kettleborough, C. A., Saldanha, J., Ansell, K. H., and Bendig, M. M. (1993) Optimization of primers for cloning libraries of mouse immunoglobulin genes using the polymerase chain reaction. Eur. J. Immunol. 23(1), 206–211.
Burton, D. R. and Barbas, C. F. (1994) Human antibodies from combinatorial libraries. Adv. Immunol. 57, 191–280.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc.
About this protocol
Cite this protocol
Das, D., Suresh, M.R. (2005). Producing Bispecific and Bifunctional Antibodies. In: Ludewig, B., Hoffmann, M.W. (eds) Adoptive Immunotherapy: Methods and Protocols. Methods in Molecular Medicine™, vol 109. Humana Press. https://doi.org/10.1385/1-59259-862-5:329
Download citation
DOI: https://doi.org/10.1385/1-59259-862-5:329
Publisher Name: Humana Press
Print ISBN: 978-1-58829-406-7
Online ISBN: 978-1-59259-862-5
eBook Packages: Springer Protocols